New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
11:22 EDTAMAGAMAG says ferumoxytol met both primary endpoints in two trials
AMAG said in trial IDA-301 the primary efficacy endpoint for U.S. regulators is the proportion of subjects who achieved a 2.0 g/dL increase in hemoglobin at any time from baseline to week 5; the primary efficacy endpoint for European Union regulators is the mean change in hemoglobin from baseline to week 5. In the IDA-301 trial, ferumoxytol achieved both primary efficacy endpoints. In IDA-302 the same primary efficacy endpoints were used and in the IDA-302 trial, ferumoxytol achieved both primary efficacy endpoints. In IDA-301, the overall rate of reported adverse events was higher in the ferumoxytol group than in the placebo group, although no new safety signals, outside of those described in the current Feraheme label, were observed in this study. In the IDA-302 trial, the overall rates of adverse events and related adverse events were comparable in ferumoxytol- and iron sucrose-treated subjects, and included many attributable to comorbid disease. However, the overall rate of SAEs, both related and unrelated as assessed by the investigator, was higher in ferumoxytol-treated subjects.
News For AMAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
12:10 EDTAMAGAMAG acquisition of Cord Blood Registry a strong fit, says Leerink
Subscribe for More Information
07:39 EDTAMAGAMAG Pharmaceuticals to host conference call
Conference call to discuss acquisition of Cord Blood Registry will be held on June 29 at 8 am. Webcast Link
07:02 EDTAMAGAMAG Pharmaceuticals to acquire Cord Blood Registry for $700M
AMAG Pharmaceuticals announced that it has entered into a definitive agreement to acquire Cord Blood Registry, or CBR, the world's largest stem cell collection and storage company serving pregnant women and their families, for $700M. The acquisition of CBR would expand AMAG's suite of maternal health offerings and add a high-margin business with complementary commercial capabilities and attractive future growth opportunities to the AMAG portfolio. The transaction is expected to further diversify AMAG's revenue base, be immediately accretive to adjusted EBITDA and earnings, and result in expense synergies of approximately $15M annually. CBR's revenue consists of upfront processing revenues for newly stored units, as well as a high-margin recurring revenue based on cumulative stored units. CBR's growing base of installed units provides for an increasing mix of revenue from storage fees. The larger and more diversified forecasted revenues that we expect as a result of this transaction are projected to allow AMAG to achieve a lower overall cost of capital, with terms that provide more flexibility and borrowing capacity to consummate future transactions. The transaction has been unanimously approved by AMAG's and CBR's boards. It is anticipated that the transaction will close in Q3.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use